Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samir Parekh

Showing results (151-160 of 162) with videos related to

Pageof 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple MyelomaSundar Jagannath, Thomas G Martin, Yi Lin, et al.
Nature Medicine|August 26, 2020
An inflammatory cytokine signature predicts COVID-19 severity and survivalDiane Marie Del Valle, Seunghee Kim-Schulze, Hsin-Hui Huang, et al.
Journal for Immunotherapy of Cancer|December 30, 2025
Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignanciesAdila Izgutdina, Tasfia Rashid, William C Temple, et al.
The New England Journal of Medicine|August 20, 2025
Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell TherapyAdolfo Aleman, Oliver Van Oekelen, David T Melnekoff, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell MalignanciesAdila Izgutdina, Tasfia Rashid, William C Temple, et al.
Haematologica|April 1, 2021
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphomaMan Chun John Ma, Saber Tadros, Alyssa Bouska, et al.
Cancer Discovery|March 17, 2025
PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant SettingMansi Saxena, Thomas U Marron, Julia Kodysh, et al.
Blood|May 13, 2025
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cellsCorynn Kasap, Adila Izgutdina, Bonell Patiño-Escobar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2025
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaHervé Avet-Loiseau, Faith E Davies, Mehmet K Samur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2025
Erratum: International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaHervé Avet-Loiseau, Faith E Davies, Mehmet K Samur, et al.
Pageof 17

Showing results (151-160 of 162) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple MyelomaSundar Jagannath, Thomas G Martin, Yi Lin, et al.
Nature Medicine|August 26, 2020
An inflammatory cytokine signature predicts COVID-19 severity and survivalDiane Marie Del Valle, Seunghee Kim-Schulze, Hsin-Hui Huang, et al.
Journal for Immunotherapy of Cancer|December 30, 2025
Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignanciesAdila Izgutdina, Tasfia Rashid, William C Temple, et al.
The New England Journal of Medicine|August 20, 2025
Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell TherapyAdolfo Aleman, Oliver Van Oekelen, David T Melnekoff, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell MalignanciesAdila Izgutdina, Tasfia Rashid, William C Temple, et al.
Haematologica|April 1, 2021
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphomaMan Chun John Ma, Saber Tadros, Alyssa Bouska, et al.
Cancer Discovery|March 17, 2025
PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant SettingMansi Saxena, Thomas U Marron, Julia Kodysh, et al.
Blood|May 13, 2025
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cellsCorynn Kasap, Adila Izgutdina, Bonell Patiño-Escobar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2025
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaHervé Avet-Loiseau, Faith E Davies, Mehmet K Samur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2025
Erratum: International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaHervé Avet-Loiseau, Faith E Davies, Mehmet K Samur, et al.
Pageof 17